' '
Deutsch | English    

Forschungsdatenbank PMU-SQQUID

Intravenous Brivaracetam in the Treatment of Status Epilepticus: A Systematic Review.
Brigo, F; Lattanzi, S; Nardone, R; Trinka, E
CNS DRUGS. 2019; 33(8): 771-781.


Nardone Raffaele
Trinka Eugen


BackgroundBrivaracetam is a high-affinity synaptic vesicle glycoprotein 2A ligand with high brain permeability and rapid onset of action. These properties make brivaracetam potentially an ideal compound in the emergency setting.ObjectiveThe objective of our study was to review the evidence about the clinical efficacy and tolerability of intravenous brivaracetam in the treatment of status epilepticus.MethodsWe systematically searched MEDLINE, EMBASE, Google Scholar, ClinicalTrials.gov, and conference proceedings to identify studies evaluating intravenous brivaracetam as treatment for status epilepticus of any type in patients of any age. Searches were conducted on 3 December, 2018.ResultsSeven studies were included (37 patients; aged 22-85years; 21 were female). The type and etiology of status epilepticus varied across studies. The number of drugs used prior to brivaracetam to treat status epilepticus ranged from 1 to 8. The time from status epilepticus onset to brivaracetam administration ranged from 0.5h to 105days. The initial brivaracetam dose ranged from 50 to 400mg. In case series, the proportion of patients achieving clinical status epilepticus cessation when brivaracetam was administered as the last drug varied from 27 to 50%; in case reports, all patients had status epilepticus cessation. The time from brivaracetam administration to status epilepticus cessation ranged from 15minto 94h. No serious adverse effects were reported.ConclusionsThe available data suggested that brivaracetam can be a safe treatment option in patients with status epilepticus. The current evidence is however hampered by several confounding factors, and controlled studies are warranted to define the actual benefit of brivaracetam for the treatment of status epilepticus.